Parameter | Base-case (range) | Source/comment |
---|---|---|
Antiviral drug costs | Â | Â |
Lamivudine (100 mg) | 2.07(1.86-2.27) | Local charge |
Adefovir (10 mg) | 2.31 (2.15-3.08) | Local charge |
Entecavir (1000 mg) | 10.20 (8–10.2) | Local charge |
Tenofovir (300 mg) | 6.00 (4.62-7.69) | The price and range were assumed |
Annual health state costs | Â | Â |
Lamivudine-resistant CHB | 138.7(104.62-209.23) | Assumed similar to naïve CHB[5] |
Multi-resistant CHB | 138.7(104.62-209.23) | Assumed similar to lamivudine-resistant CHB[5] |
Virological response | 138.7(104.62-209.23) |     [5] |
Compensated cirrhosis | 235.37(209.23-313.85) |     [5] |
Decompensated cirrhosis | 2122.55(1569.23-2615.38) |     [5] |
HCC | 5914.78(5230.77-10461.54) |     [5] |
Liver transplantation | 46152.94(44984.62-52307.69) |     [5] |
Post-liver-transplantation | 7691.63(7323.08-9415.38) |     [5] |
Utilities (quality of life) | Â | Â |
Lamivudine-resistant CHB | 0.52(0.5-0.7) |     [34] |
Multi-resistant CHB | 0.52(0.5-0.7) |     [34] |
Virological response | 0.71(0.65-0.8) |     [34] |
Compensated cirrhosis | 0.57(0.5-0.7) |     [34] |
Decompensated cirrhosis | 0.26(0.2-0.35) |     [34] |
HCC | 0.31(0.24-0.38) |     [34] |
Liver transplantation | 0.7(0.54-0.76) |     [34] |